![](https://news.europawire.eu/wp-content/uploads/2021/08/Roche-FACADE-144x144.jpg)
(IN BRIEF) Roche provided an update on its Phase III SKYSCRAPER-01 study, evaluating tiragolumab in combination with Tecentriq® for patients with PD-L1-high, advanced, or metastatic non-small cell lung cancer (NSCLC). The study did not meet its primary endpoint of improving … Read the full press release